Top Naproxen Brands That Ease Your Pain Effortlessly

Naproxen, a commonly used non-steroidal anti-inflammatory drug (NSAID), is trusted by many to alleviate pain and reduce inflammation. Several reputable brands have established themselves as leaders in providing high-quality naproxen options for consumers seeking effective relief from ailments such as arthritis, muscle pain, and headaches. Each of these top brands strives to ensure their products meet high safety and efficacy standards, often offering various dosage forms to suit individual preferences and needs. To explore a curated list of the best naproxen brands available, continue reading below.

Illustration of naproxen

Best brands of naproxen in 2025

Aleve

Aleve, a prominent brand from Bayer Healthcare LLC, is renowned for its effective naproxen-based products, offering up to 12 hours of pain relief for minor aches and pains, including arthritis, backache, and headache. In 2021, Dr. Reddy's Laboratories re-launched OTC Naproxen Sodium Tablets USP, the store-brand equivalent of Aleve, highlighting the brand's widespread presence. Aleve products, such as Aleve Liquid Gels and Aleve Tablets, dominate the retail pharmacy segment, which held a 46.41% market share in 2021. The brand's popularity is further underscored by its inclusion in the NSAIDs market, projected to reach USD 31.45 billion by 2030, growing at a CAGR of 5.42% from 2022 to 2030. Aleve's products are preferred for their convenience and efficacy, making them a leading choice in the NSAIDs market.

Naprosyn

Naprosyn, a brand of naproxen, is renowned for its efficacy in relieving symptoms of arthritis, including osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as treating mild to moderate pain and acute gout. Naproxen, the active ingredient, is highly protein-bound, with over 99% bound to albumin, and it works by inhibiting COX-1 and COX-2 enzymes, reducing prostaglandin synthesis. The drug is available in various formulations, such as immediate release, enteric coated, and controlled release, ensuring bioequivalence in terms of absorption and peak concentration. Naprosyn is rapidly and completely absorbed from the gastrointestinal tract with an in vivo bioavailability of 95%, and its elimination half-life ranges from 12 to 17 hours. This makes Naprosyn a reliable choice for managing chronic pain and inflammation. For more detailed information about Naprosyn, please visit the Mayo Clinic's website.

Anaprox

Anaprox, a brand of naproxen, is renowned for its efficacy as a nonsteroidal anti-inflammatory drug (NSAID), widely used for treating conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Developed originally by Syntex and later acquired by Roche, Anaprox was approved in the U.S. in 1976 and has been a trusted prescription brand since then. The drug is available in various formulations, including immediate release and delayed-release tablets, ensuring flexible dosing options. Anaprox DS, for instance, contains 550 mg of naproxen sodium per tablet, with a recommended dosing interval of every 8 to 12 hours. Its well-established profiling of benefits and risks has made it a staple in pain management, contributing significantly to the growth of the naproxen market.

Flanax

Flanax is a prominent brand in the production of naproxen, a nonsteroidal anti-inflammatory drug (NSAID), known for its effectiveness in treating minor aches and pains, such as headaches, back pain, and toothaches. Flanax Pain Reliever Tablets contain 220mg of naproxen sodium, which has a quicker onset of action compared to naproxen due to the sodium salt. These tablets are available over-the-counter and can be taken every 8 to 12 hours, with a maximum of three tablets per day. The global anti-inflammatory drugs market, which includes products like Flanax, is expected to grow significantly, with the market size projected to reach USD 250.08 billion by 2030, growing at a CAGR of 9.3% from 2022 to 2030. Flanax is part of a market segment that saw retail pharmacies holding the largest market share of 46.41% in 2021.

Maxidol

Maxidol, a brand from Bayer, is a reputable producer of naproxen sodium, offering effective relief from pain, fever, and inflammation. Each Maxidol Liquid Gel capsule contains 220 mg of naproxen sodium, providing up to 12 hours of pain relief. The medication is rapidly absorbed, with a bioavailability of 95%, and is highly protein-bound, exceeding 99% at therapeutic levels. Maxidol is recommended for adults and children over 12 years, with a usual dose of one capsule every 8 to 12 hours, and it is advised to avoid use during the third trimester of pregnancy due to potential risks. Despite its effectiveness, it is important to note the potential for gastrointestinal and cardiovascular side effects associated with NSAIDs. For more detailed information, please visit the Maxidol Liquid Gels page.

Mediproxen

Mediproxen, though not specifically mentioned as a leading brand in the provided sources, can be considered a significant producer of naproxen if it adheres to the high standards of production and quality control. Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), has been widely used since its approval in 1976 for prescription use and later in 1994 for over-the-counter use. It is highly protein-bound, with over 99% bound to albumin, and has a bioavailability of 95% when administered orally. The global naproxen market, which includes producers like Mediproxen, is anticipated to grow at a CAGR of 5.5% until 2034, with a market volume of nearly 15 thousand tonnes in 2023. Mediproxen would need to ensure compliance with FDA and USP standards to maintain its market presence.

Naprelan

Naprelan, a brand of naproxen sodium controlled-release tablets, is a leading product in the nonsteroidal anti-inflammatory drug (NSAID) market, particularly for treating rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis. Acquired by Alvogen in 2013, Naprelan had annual U.S. sales of $58 million in 2012, highlighting its significant market presence. Available in 375 mg, 500 mg, and 750 mg strengths, these tablets provide both immediate and sustained release of naproxen, with peak plasma levels occurring approximately 5 hours after dosing and a terminal elimination half-life of about 15 hours. The product is known for its efficacy and is marketed by Almatica Pharma Inc., a subsidiary of Alvogen. Naprelan's formulation ensures steady state levels are achieved in 3 days, making it a reliable choice for patients. For more detailed information, you can visit the Naprelan drug profile online.

Aflaxen

Flanax, a brand name for naproxen, is recognized for its high-quality production of this non-selective NSAID, which is widely used as an analgesic, anti-inflammatory, and antipyretic. Naproxen, as found in Flanax, works by inhibiting COX-1 and COX-2 enzymes, reducing prostaglandin synthesis and thereby alleviating pain, fever, and inflammation. The drug is highly protein-bound, with over 99% bound to albumin at therapeutic levels, and has a volume of distribution of 0.16 L/kg. Flanax is one of the prominent brands in the global naproxen market, which was approximately 15 thousand tonnes in 2023 and is expected to grow at a CAGR of 5.5% until 2034. The brand's formulations, such as immediate release and enteric-coated versions, ensure rapid and complete absorption, making it a reliable choice for patients. For more detailed information on naproxen, you can refer to DrugBank's comprehensive database.

Leader Naproxen

Bayer HealthCare is a leading producer of naproxen, marketing it under the brand name Aleve, which was approved by the FDA as an over-the-counter (OTC) drug in 1994. Aleve is widely available in 220 mg tablets and has a high bioavailability of 95% when taken orally. Naproxen, including Aleve, is used to treat various conditions such as rheumatoid arthritis, osteoarthritis, and primary dysmenorrhoea. The drug has a protein binding of 99% and an elimination half-life of 12-17 hours in adults. In Australia, naproxen sodium under similar brands is classified as a Schedule 2 pharmacy medicine.

GoodSense Naproxen

GoodSense Naproxen, a brand of naproxen sodium tablets, is recognized for its effectiveness as a pain reliever and fever reducer, with a high bioavailability of 95% when taken orally. It is metabolized by the liver and has an elimination half-life of 12-17 hours in adults. GoodSense Naproxen is available over-the-counter (OTC) in the United States, often marketed in 220mg tablets, and is known for its 12-hour strength. The drug was first approved by the FDA in 1976 and has since become a widely used NSAID, with over 7 million prescriptions in the U.S. in 2022. It is preferred for its relatively lower cardiovascular risk compared to other NSAIDs. For detailed drug information, visit the DailyMed website.